SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
MaxCyte, Inc. Common Stock
MXCT
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
Last trade$1.20
Day change+$0.02 (+1.69%)
Day range$1.17 – $1.26
Volume777,901
Market cap$122M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$121.84M
Price / earnings
—
Price / book
0.81×
Price / sales
3.54×
EV / sales
3.16×
EV / EBITDA
-4.7×
Profitability
Earnings per share
-$0.27
Return on assets
-15.33%
Return on equity
-18.54%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
7.83×
Quick ratio
7.37×
Cash ratio
0.84×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$21.45M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MXCT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$10.15M
$7.27M
$9.65M
$7.3M
$6.83M
$8.51M
$10.39M
$8.69M
Cost of revenue
$1.68M
$1.68M
$1.57M
$1.61M
$1.6M
$1.52M
$1.5M
$2.28M
Gross profit
$8.47M
$5.6M
$8.08M
$5.69M
$5.23M
$6.99M
$8.89M
$6.41M
Selling, general and administrative
$10.77M
$10.62M
$9.39M
$8.99M
$9.96M
$13.87M
$14.22M
$13.68M
Research and development
$2.87M
$4.25M
$3.86M
$3.34M
$5.32M
$6.27M
$5.9M
$4.61M
Total operating expenses
$14.51M
$15.83M
$14.27M
$16.92M
$19.38M
$21.22M
$21.19M
$19.31M
Operating income
-$6.04M
-$10.23M
-$6.19M
-$11.23M
-$14.15M
-$14.23M
-$12.3M
-$12.9M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$4.76M
-$8.87M
-$4.75M
-$9.6M
-$12.42M
-$12.36M
-$10.26M
-$10.6M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$4.76M
-$8.87M
-$4.75M
-$9.6M
-$12.42M
-$12.36M
-$10.26M
-$10.6M
Net income attributable to common shareholders
-$4.76M
-$8.87M
-$4.75M
-$9.6M
-$12.42M
-$12.36M
-$10.26M
-$10.6M
EBITDA
-$5.14M
-$9.25M
-$5.14M
-$3.54M
-$10.02M
-$13.13M
-$11.2M
-$11.84M
Basic earnings per share
-$0.05
-$0.08
-$0.04
-$0.09
-$0.12
-$0.12
-$0.10
-$0.10
Diluted earnings per share
-$0.05
-$0.08
-$0.04
-$0.09
-$0.12
-$0.12
-$0.10
-$0.10
Recent news
Company coverage with links to the original publishers.
Keros Therapeutics reported Q3 2026 earnings of $0.7 per share, beating consensus estimates of a $0.96 loss, with a 172.92% earnings surprise. Revenues reached $40.01 million, surpassing estimates by 197.47% compared to $14.26 million year-ago. However, the stock has underperformed the market, down 46.8% year-to-date versus the S&P 500's 12.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Fortrea Holdings Inc. (FTRE) reported Q3 earnings of $0.28 per share, beating consensus estimates of $0.24, and revenues of $691.5 million, exceeding expectations by 3.18%. The company has outperformed the market by 50% year-to-date versus the S&P 500's 13.1% gain. However, the stock received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Emergent Biosolutions stock jumped 14.4% following positive news including a $24 million BARDA contract for Cyfendus, a three-year Canadian government contract for Narcan nasal spray, and a $75 million debt repurchase. However, the company faces headwinds with expected quarterly losses of $0.37 per share and revenues declining 46.6% year-over-year. With unchanged earnings estimates and a Zacks Rank #3 (Hold) rating, analysts question whether the rally can sustain.
The North America non-viral transfection reagents market is projected to grow from USD 0.34 billion in 2026 to USD 0.70 billion by 2035, representing an 8.5% CAGR. Growth is driven by rising investment in cell and gene therapy, increasing demand for nucleic acid-based treatments, and advances in scalable, low-toxicity delivery technologies. Physical methods like electroporation currently lead the market, while chemical delivery vectors are expected to show fastest growth. Clinical applications are projected to register the highest CAGR as cell and gene therapy programs advance.
U.S. stock futures showed mixed performance on Wednesday with Dow Jones futures falling while S&P 500 and Nasdaq 100 rose. President Trump visited China with major tech leaders including Nvidia's Jensen Huang, Tesla's Elon Musk, and Apple's Tim Cook. Key movers included Nextpower surging on strong earnings, MaxCyte jumping on better-than-expected results, and Red Cat Holdings plunging after a public offering announcement. The 10-year Treasury yield stood at 4.46%, with markets pricing a 97.6% likelihood of unchanged Fed rates in June.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.